Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Crosses Above Two Hundred Day Moving Average – Should You Sell?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) passed above its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of $85.18 and traded as high as $85.92. Dianthus Therapeutics shares last traded at $85.81, with a volume of 1,679,417 shares changing hands.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on DNTH. Wedbush lifted their price target on shares of Dianthus Therapeutics from $105.00 to $122.00 and gave the company an “outperform” rating in a research note on Wednesday, August 5th. Raymond James Financial reiterated a “strong-buy” rating and issued a $131.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, August 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Thursday, October 15th. Roth Capital began coverage on shares of Dianthus Therapeutics in a research note on Tuesday, October 27th. They issued a “buy” rating and a $113.00 price objective on the stock. Finally, Truist Financial lifted their target price on Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $128.54.

Dianthus Therapeutics Price Performance

The stock has a market capitalization of $4.70 billion, a P/E ratio of -20.68 and a beta of 1.47. The company has a 50 day simple moving average of $91.11 and a 200-day simple moving average of $85.18.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings results on Wednesday, November 4th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.94) by $0.13. The company had revenue of $1.21 million for the quarter, compared to analyst estimates of $0.46 million. Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. As a group, equities analysts forecast that Dianthus Therapeutics, Inc. will post -3.81 earnings per share for the current fiscal year.

Insider Buying and Selling at Dianthus Therapeutics

In other Dianthus Therapeutics news, Director Simon Read sold 2,778 shares of Dianthus Therapeutics stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $117.55, for a total transaction of $326,553.90. Following the completion of the sale, the director owned 2,778 shares of the company’s stock, valued at $326,553.90. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Anne McGeorge sold 7,750 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $109.01, for a total value of $844,827.50. Following the completion of the sale, the director directly owned 1,250 shares of the company’s stock, valued at approximately $136,262.50. This represents a 86.11% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 242,429 shares of company stock worth $26,118,913 in the last ninety days. Insiders own 3.02% of the company’s stock.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of hedge funds have recently modified their holdings of the company. BlackRock Inc. purchased a new position in shares of Dianthus Therapeutics during the second quarter valued at approximately $401,990,000. Wellington Management Group LLP increased its holdings in Dianthus Therapeutics by 24.4% in the 2nd quarter. Wellington Management Group LLP now owns 3,229,882 shares of the company’s stock worth $314,849,000 after buying an additional 634,099 shares in the last quarter. Jennison Associates LLC purchased a new stake in Dianthus Therapeutics during the 1st quarter valued at $40,713,000. Assenagon Asset Management S.A. lifted its holdings in Dianthus Therapeutics by 160.9% in the third quarter. Assenagon Asset Management S.A. now owns 732,246 shares of the company’s stock valued at $64,474,000 after acquiring an additional 451,597 shares during the period. Finally, Spruce Street Capital LP bought a new position in shares of Dianthus Therapeutics in the 2nd quarter worth approximately $34,587,464. Hedge funds and other institutional investors own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines for autoimmune and inflammatory diseases. The company’s research centers on the complement system, an important part of the immune response that can contribute to tissue damage and disease when improperly activated.

Dianthus’ lead product candidate, DNTH103, is an investigational, fully human monoclonal antibody designed to selectively inhibit C1s, a key protein in the classical complement pathway.